Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.86
-0.42 (-4.09%)
At close: Jun 2, 2026, 4:00 PM EDT
9.90
+0.04 (0.41%)
After-hours: Jun 2, 2026, 4:00 PM EDT
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Atara Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $13.67. The average 1-year stock price forecast is 38.64% higher than the current stock price, while the lowest is $10 (+1.42%) and the highest is $18 (+82.56%).
Price Target: $13.67 (+38.64%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 | 1 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Freedom Capital Markets | Freedom Capital Markets | Hold Upgrades $4 → $10 | Hold | Upgrades | $4 → $10 | +1.42% | May 18, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $13 | Buy | Maintains | $13 | +31.85% | May 13, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $18 | Buy | Maintains | $18 | +82.56% | Mar 30, 2026 |
Financial Forecast
Revenue This Year
658.00K
from 120.77M
Decreased by -99.46%
Revenue Next Year
51.33M
from 658.00K
Increased by 7,700.15%
EPS This Year
-1.19
from 2.57
EPS Next Year
1.42
from -1.19
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 800,000 | ||
| Avg | 658,000 | ||
| Low | 516,000 |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -99.3% | ||
| Avg | -99.5% | ||
| Low | -99.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.14 | ||
| Avg | -1.19 | ||
| Low | -1.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.